CD47 and neoplasm: In in vitro and in vivo models, the CD47 blocker ALX148 has been shown to stimulate anti-tumor properties of innate immune cells by promoting DC activation, macrophage phagocytosis, and shifting TAMs toward an inflammatory phenotype.